Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
Özet
Alopesi, genetik, hormonal ve otoimmün faktörlerin etkisiyle ortaya çıkan, kısmi veya tam saç kaybına yol açan karmaşık bir dermatolojik hastalıktır. Alopesinin farmakolojik tedavisi esas olarak saç folikülü aktivitesinin artırılması, bağışıklık yanıtlarının düzenlenmesi ve androjen aracılı yolakların inhibisyonuna odaklanmaktadır. Günümüzde onaylanmış tedaviler arasında yer alan minoksidil, potasyum kanallarını açarak foliküler kan akışını artırır ve anajen fazın süresini uzatır. Finasterid ve dutasterid ise 5α-redüktaz inhibitörleri olarak etki gösterir. Topikal kortikosteroidler ve immünmodülatör ajanlar, foliküler inflamasyonu azaltarak alopesi areata tedavisinde önemli bir rol oynamaktadır. Son yıllarda, JAK inhibitörleri hücre içi sitokin sinyallemesini hedefleyerek dirençli vakalarda saç yeniden büyümesini teşvik etme açısından klinik olarak umut verici sonuçlar sunmuştur. Ayrıca, prostaglandin analogları (örneğin latanoprost ve bimatoprost) saç foliküllerini uyarıcı etkiler göstermekte, PDE4 inhibitörleri ise yeni antiinflamatuvar potansiyelleriyle dikkat çekmektedir. Devam eden klinik araştırmalar, bu farmakoterapilerin etkinliğini, güvenliliğini ve uzun dönem sonuçlarını iyileştirmeye yönelik çalışmalarla sürmektedir.
Referanslar
Dolaş, N. Alopesi areata, androgenetik alopesi ve telogen effluviumdan oluşan saç kaybı ile giden sayrılıkların etyolojisinde stresli yaşam olaylarının varlığının değerlendirilmesi, bu gruplardaki anksiyete ve depresyon belirtilerinin kendi aralarında ve sağlıklı gönüllülerden oluşan kontrol grubu ile karşılaştırılması (Doctoral dissertation, Dokuz Eylul Universitesi (Turkey)), 2014.
Aldemir, S., Erpolat, S., Dalbudak, E., Tan, S., & Topcu, M. Diffüz alopesili kadınlarda öfke, anksiyete ve depresyon. Dicle Tıp Dergisi: 2015;42(3), 335-341.
Kutlubay, Z., Baglam, S., Engin, B., & Serdaroglu, S. Erkeklerde androgenetik alopesi/Male androgenetic alopecia. Türkderm: Türk Deri Hastalıkları ve Frengi Arşivi= Turkderm: Turkish Archives of Dermatology and Venereology: 2014;48, 36.
Doğramacı, A. Ç., & Sultan ÖNCÜ, I. N. Postmenopozal Alopesiler ve Hirşutizm. Türkiye Klinikleri Kozmetik Dermatoloji Özel Dergisi: 2018;11(4).
Bakayoko, N. N. M. Yeni Ürün Geliştirme ve Işletmelerin Rekabet Gücü: Kozmetik Endüstrisi Örneği (Master's thesis, Necmettin Erbakan University (Turkey)), 2022.
Duygu, Ç. Foliküler saç greftinin yaşayabilirliğine trombositten zengin plazmanın etkisi: Deneysel çalışma/Effect of platelet rich plasma on hair follicle graft survival: Experimental study (Doctoral dissertation), 2014.
Turan, I. K. Androgenetik Alopesi ve Telogen Effluvium Tanılı Kadın Hastalarda Saç ve Saçlı Deri Trikoskopisi (Doctoral dissertation, Dokuz Eylul Universitesi (Turkey)), 2020.
Köroğlu, K. Alopecia Areatalı Hastalarda Asprosin Ve Adiponektin Seviyelerinin İncelenmesi (Doctoral dissertation), 2024.
Otberg, N., Finner, A. M., & Shapiro, J. Androgenetic alopecia. Endocrinology and metabolism clinics of North America:2007; 36(2), 379-398.
Pratt, C. H., King, L. E., Messenger, A. G., Christiano, A. M., & Sundberg, J. P. Alopecia areata. Nature reviews Disease primers:2017; 3(1), 1-17.
Liyanage, D., & Sinclair, R. Telogen effluvium. Cosmetics:2016;3(2), 13.
Sperling, L. C. Scarring alopecia and the dermatopathologist. Journal of cutaneous pathology:2001;28(7), 333-342.
Gupta, A. K., Bamimore, M. A., Williams, G., & Talukder, M. Comparative Efficacy of Minoxidil and 5‐Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta‐Analysis Study of Current Empirical Evidence. Journal of Cosmetic Dermatology:2025; 24(7), e70320.
Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA dermatology:2022; 158(3), 266-274.
Kim, J., Song, S. Y., & Sung, J. H. Recent Advances in Drug Development for Hair Loss. International Journal of Molecular Sciences:2025;26(8), 3461.
Gupta, A. K., Talukder, M., Venkataraman, M., & Bamimore, M. A. Minoxidil: a comprehensive review. Journal of Dermatological Treatment:2022; 33(4), 1896-1906.
Shorter, K.; Farjo, N.P.; Picksley, S.M.; Randall, V.A. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008, 22, 1725–1736.
Lachgar, S.; Charveron, M.; Gall, Y.; Bonafe, J.L. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br. J. Dermatol. 1998, 138, 407–411.
Kwack, M.H.; Kang, B.M.; Kim, M.K.; Kim, J.C.; Sung, Y.K. Minoxidil activates beta-catenin pathway in human dermal papilla cells: A possible explanation for its anagen prolongation effect. J. Dermatol. Sci. 2011, 62, 154–159.
Shapiro, J., Sicco, K. L., Otberg, N., Cummins, D., & Tuan, H. H. (Eds.). Hair loss and restoration. CRC Press, 2024.
Adil, A.; Godwin, M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J. Am.Acad. Dermatol. 2017, 77, 136–141.e5.
van Zuuren, E.J.; Fedorowicz, Z.; Carter, B. Evidence-based treatments for female pattern hair loss: A summary of a Cochrane systematic review. Br. J. Dermatol. 2012, 167, 995–1010.
Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. Minoxidil and its use in hair disorders: a review. Drug design, development and therapy, 2019, 2777-2786.
Reddy, M. S., Mutalik, S., & Rao, G. V. Preparation and evaluation of minoxidil gels for topical application in Alopecia opical application in Alopecia. Indian journal of pharmaceutical sciences, 2006;68(4), 432-8.
Friedman, E. S., Friedman, P. M., Cohen, D. E., & Washenik, K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. Journal of the American Academy of Dermatology, 2002;46(2), 309-312.
Yorulmaz, A. Androgenetik alopesi. Çağdaş Tıp Dergisi, 2016; 6(3), 248-254.
An, S.; Zheng, M.; Park, I.G.; Noh, M.; Sung, J.H. Differential expression of androgen receptor and 5-alpha reductase isoforms in skin cells. Arch. Dermatol. Res. 2024, 317, 138.
Chen, L.; Zhang, J.; Wang, L.; Wang, H.; Chen, B. The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. Aesthetic Plast. Surg. 2020, 44, 962–970.
Diviccaro, S.; Melcangi, R.C.; Giatti, S. Post-finasteride syndrome: An emerging clinical problem. Neurobiol. Stress. 2020, 12, 100209. [CrossRef]
Safety update: Psychiatric and sexual adverse effects with finasteride. Drug Ther. Bull. 2024, 62, 101.
Almudimeegh, A.; AlMutairi, H.; AlTassan, F.; AlQuraishi, Y.; Nagshabandi, K.N. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: A systematic review. Dermatol. Rep. 2024, 16, 9909.
Herz-Ruelas, M.E.; Alvarez-Villalobos, N.A.; Millan-Alanis, J.M.; de Leon-Gutierrez, H.; Ocampo-Garza, S.S.; Gomez-Flores, M.;
Grimalt, R. Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review. Skin. Appendage Disord. 2020, 6, 338–345.
Harel, S.; Higgins, C.A.; Cerise, J.E.; Dai, Z.; Chen, J.C.; Clynes, R.; Christiano, A.M. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci. Adv. 2015, 1, e1500973.
Wang, E. H., Sallee, B. N., Tejeda, C. I., & Christiano, A. M.. JAK Inhibitors for Treatment of Alopecia Areata. Journal of Investigative Dermatology, 138(9), 2018;1911-1916.
Kwon, O.; Senna, M.M.; Sinclair, R.; Ito, T.; Dutronc, Y.; Lin, C.Y.; Yu, G.; Chiasserini, C.; McCollam, J.; Wu, W.S.; et al. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am. J. Clin. Dermatol. 2023, 24, 443–451.
Javed, T. FDA approval of deuruxolitinib: a new treatment option for severe alopecia areata. Clinical Research, 2024;5(1), 1-3.
Ramírez-Marín, H. A., & Tosti, A. Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. Drug design, development and therapy, 2023;363-374.
Wang, Y.; Huh, Y.; Lejeune, A. Population exposure-response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata. CPT Pharmacomet. Syst. Pharmacol. 2025, 14, 389–402.
Maeshima, T.; Aisu, S.; Ohkura, N.; Watanabe, M.; Itagaki, F. The Association Between Deep Vein Thrombosis, Pulmonary Embolism, and Janus Kinase Inhibitors: Reporting Status and Signal Detection in the Japanese Adverse Drug Event Report Database. Drugs Real. World Outcomes 2024, 11, 369–375.
Di Napoli, R., Richez, C., Scavone, C., Singier, A., Demourgues, M., Mascolo, A., ... & Salvo, F. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. Drug safety, 2025;48(8), 943.
Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010;28(3):611-8.
Sadeghzadeh Bazargan, A., Tavana, Z., Dehghani, A., Jafarzadeh, A., Tabavar, A., Alavi Rad, E., & Goodarzi, A. (2024). The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial. Journal of Cosmetic Dermatology, 23(2), 543-551.
Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol 2009;50(2):113-4.
Camacho-Martínez FM. Hair loss in women. Semin Cutan Med Surg 2009;28(1):19-32.
Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010;28(3):611-8.
Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol 2015;73(4):705-6.
Sovak, M., Seligson, A. L., Kucerova, R., Bienova, M., Hajduch, M., & Bucek, M. (2002). Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Dermatologic surgery, 28(8), 678-685.
Vexiau, P., Chaspoux, C., Boudou, P., Fiet, J., Jouanique, C., Hardy, N., & Reygagne, P. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology, 2002;146(6), 992-999.
Fabbrocini G, Cantelli M, Masarà A, et al. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol 2018;4(4):203-211.
Devjani, S., Ezemma, O., Kelley, K. J., Stratton, E., & Senna, M. Androgenetic alopecia: therapy update. Drugs, 2023;83(8), 701-715.
Johnson, D. B., & Sonthalia, S. (2018). Flutamide.
Iguchi T, Tamada S, Kato M, Yasuda S, Otoshi T, Hamada K, Yamasaki T, Nakatani T. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study. Int J Clin Oncol. 2019 Jul;24(7):848-856.
Anastassakis, K. Ketoconazole. In Androgenetic Alopecia From A to Z: Vol. 2 Drugs, Herbs, Nutrition and Supplements 2022;(pp. 133-139). Cham: Springer International Publishing.
Pierard-Franchimont, C., Pierard, G. E., Arrese, J. E., & De Doncker, P. (2001). Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology, 202(2), 171-176.
Tynes, B. E., Johnson, C. D., Vaish, M. H., Abbott, B., Vučenović, J., Varrassi, G., ... & Vaish, M. Ketoconazole shampoo for seborrheic dermatitis of the scalp: a narrative review. Cureus, 2024;16(8).
Shin, D. W. The physiological and pharmacological roles of prostaglandins in hair growth. The Korean Journal of Physiology & Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2022;26(6), 405-413.
Nestor, M. S., Ablon, G., Gade, A., Han, H., & Fischer, D. L. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Journal of cosmetic dermatology, 2021;20(12), 3759-3781.
Law, S. K. Bimatoprost in the treatment of eyelash hypotrichosis. Clinical Ophthalmology, 2010;349-358.
Lensing, M., & Jabbari, A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Frontiers in immunology, 2022;13, 955035.
Fischer, T. W., Trüeb, R. M., Hänggi, G., Innocenti, M., & Elsner, P. Topical melatonin for treatment of androgenetic alopecia. International journal of trichology, 2012;4(4), 236-245.
Ryu, Y.C.; Lee, D.H.; Shim, J.; Park, J.; Kim, Y.R.; Choi, S.; Bak, S.S.; Sung, Y.K.; Lee, S.H.; Choi, K.Y. KY19382, a novel activator of Wnt/beta-catenin signalling, promotes hair regrowth and hair follicle neogenesis. Br. J. Pharmacol. 2021, 178, 2533–2546.
Biosplice Therapeutics, I. A Study of SM04554 Applied Topically to the Scalp of Male Subjects with Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing; Biosplice Therapeutics, Inc.: San Diego, CA, USA, 2020.
JW Pharmaceutical, Inc. Hair Loss Treatment by JW0061-Mediated Wnt Modulation for “Growth in Hair Length & Follicular Number”. 2022. Available online: https://www.jw-pharma.co.kr/pharma/en/prcenter/all_view.jsp?contentsCd=230103120310932ATI8D (accessed on 10 February 2025).
Adly, M.A.; Assaf, H.A.; Pertile, P.; Hussein, M.R.; Paus, R. Expression patterns of the glial cell line-derived neurotrophic factor, neurturin, their cognate receptors GFRalpha-1, GFRalpha-2, and a common signal transduction element c-Ret in the human skin hair follicles. J. Am. Acad. Dermatol. 2008, 58, 238–250.
Antonini, D.; Sibilio, A.; Dentice, M.; Missero, C. An Intimate Relationship between Thyroid Hormone and Skin: Regulation of Gene Expression. Front. Endocrinol. 2013, 4, 104.
Zhu, P.; Deng, W.; Yu, J.; Yang, S. Thyroid Hormone Receptor Agonist Promotes Hair Growth in Mice. Clin. Cosmet. Investig Dermatol. 2022, 15, 319–330.
Technoderma Medicines, Inc. A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia. 2024. Available online: https://adisinsight. springer.com/trials/700361593 (accessed on 10 February 2025).
Zheng, M.; Choi, N.; Jang, Y.; Kwak, D.E.; Kim, Y.; Kim, W.S.; Oh, S.H.; Sung, J.H. Hair growth promotion by necrostatin-1s. Sci.Rep. 2020, 10, 17622.
Jelinek, D.; Flores, A.; Uebelhoer, M.; Pasque, V.; Plath, K.; Iruela-Arispe, M.L.; Christofk, H.R.; Lowry, W.E.; Coller, H.A. Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J. Vis. Exp. 2018, 136, 57760.
Flores, A.; Schell, J.; Krall, A.S.; Jelinek, D.; Miranda, M.; Grigorian, M.; Braas, D.; White, A.C.; Zhou, J.L.; Graham, N.A.; et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat. Cell Biol. 2017, 19, 1017–1026.
Pelage Pharmaceuticals, Inc. Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1 NEWS PROVIDED BY Pelage Pharmaceuticals. Available online: https://www.prnewswire.com/news-releases/pelage-pharmaceuticals-advances-clinical-program-with-first-patientsdosed-in-phase-2-study-for-hair-loss-and-gv-led-14m-series-a-1-302220301.html (accessed on 10 February 2025).
Suarez-Farinas, M.; Ungar, B.; Noda, S.; Shroff, A.; Mansouri, Y.; Fuentes-Duculan, J.; Czernik, A.; Zheng, X.; Estrada, Y.D.; Xu, H.;et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J. Allergy Clin. Immunol. 2015, 136, 1277–1287.
Keren, A.; Shemer, A.; Ullmann, Y.; Paus, R.; Gilhar, A. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J. Dermatol. Sci. 2015, 77, 74–76.
Terzi, E. Topikal% 1 Pimekrolimus Tedavisine Cevap Veren Bir Alopesi Areata Olgusu. Çağdaş Tıp Dergisi,2016; 6(3), 218-220.
James WD, Elston D, Treat JR, Rosenbach MA, Neuhaus I. Diseases of the Skin Appendages. Andrews’ diseases of the skin: clinical dermatology. 13th ed. Philadelphia: Elsevier; 2019: p.750-2.
Wasserman, D., Guzman‐Sanchez, D. A., Scott, K., & McMichael, A. Alopecia areata. International journal of dermatology, 2007;46(2), 121-131.
Tosti A, Piraccini BM, Pazzaglia M, et al.Clobetasolpropionate 0.05% under occlusion in the treatment ofalopecia totalis/universalis. J Am Acad Dermatol 2003; 49:96–98.
